Stealth BioTherapeutics has today announced an award from our Business Engagement Fund to support a new collaboration to evaluate the effects of their compound SBT-589 on biomarkers of disease in a mouse model of Leigh syndrome, a rare mitochondrial disorder:
nmgn.mrc.ukri.org/news/busines...
nmgn.mrc.ukri.org/news/busines...
Business Engagement Fund award to support mitochondrial disease research | National Mouse Genetics Network
Stealth BioTherapeutics, a commercial-stage biotechnology company focused on the discovery, development, and commercialisation of novel therapies for diseases involving mitochondrial dysfunction, have...
nmgn.mrc.ukri.org
March 23, 2026 at 2:32 PM
Stealth BioTherapeutics has today announced an award from our Business Engagement Fund to support a new collaboration to evaluate the effects of their compound SBT-589 on biomarkers of disease in a mouse model of Leigh syndrome, a rare mitochondrial disorder:
nmgn.mrc.ukri.org/news/busines...
nmgn.mrc.ukri.org/news/busines...
Stealth BioTherapeutics Secures Grant for Mitochondrial Disease Research Breakthrough#United_Kingdom#Stealth_BioTherapeutics#Mitochondrial_Disease#Needham,_Massachusetts#SBT-589
Stealth BioTherapeutics Secures Grant for Mitochondrial Disease Research Breakthrough
Stealth BioTherapeutics has received a significant grant from the MRC Business Engagement Fund for pioneering research into mitochondrial disease treatments via SBT-589.
third-news.com
March 23, 2026 at 12:23 PM
Stealth BioTherapeutics Secures Grant for Mitochondrial Disease Research Breakthrough#United_Kingdom#Stealth_BioTherapeutics#Mitochondrial_Disease#Needham,_Massachusetts#SBT-589
